RARE - Ultragenyx Pharmaceutical Inc.
| Previous Close | 66.04 |
| Open | 67.86 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 2200 |
| Day's Range | 63.38 - 67.91 |
| 52 Week Range | 41.67 - 90.98 |
| Volume | 677,628 |
| Avg. Volume | 477,451 |
| Market Cap | 3.249B |
| Beta (3Y Monthly) | 3.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.99 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.78 |
Markit•12 days agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- GlobeNewswire•12 days ago
Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•17 days ago
Ultragenyx Reports Top-line Data From Gene Therapy Candidate
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
- GlobeNewswire•18 days ago
Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline positive safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. “Data from the first two dose cohorts continue to demonstrate an acceptable initial safety profile and evidence of clinical activity, with one new patient achieving normalization of ureagenesis in Cohort 2 at 24 weeks,” said Eric Crombez, M.D., Chief Medical Officer of the Ultragenyx Gene Therapy development unit.
- GlobeNewswire•19 days ago
Ultragenyx to Present at Jefferies Gene Therapy Summit
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Jefferies Gene Therapy Summit on Thursday, September 27, 2018 at 8:00am ET in New York. The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
- ACCESSWIRE•20 days ago
Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen
NEW YORK, NY / ACCESSWIRE / September 25, 2018 / U.S. markets closed lower Monday as trade tensions heated up. The Trump administration imposed a tariff of 10 percent on over $200 billion, which could ...
- Zacks•25 days ago
Ultragenyx's Shares Surge More Than 80% in the Year So Far
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Markit•27 days agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- GlobeNewswire•28 days ago
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer, effective September 28, 2018. In this newly created role, Dr. Hogenhuis will oversee Global Commercial Operations, Business Development and Technical Operations functions.
Markit•last monthSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
Markit•last monthSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Markit•last monthSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- Zacks•2 months ago
Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data
Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.
- GlobeNewswire•2 months ago
Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Ultragenyx’s most recent proposal to submit a New Drug Application (NDA) for UX007 for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) based on existing data. “We appreciate FDA’s review of multiple data submissions and collaboration with us to develop a path for an early filing, and it is our commitment to get this important potential treatment to patients with this serious disease as quickly as possible,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- Zacks•2 months ago
Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval
Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.
- GlobeNewswire•2 months ago
Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII
Mepsevii is now approved for use in all 28 EU countries and in Iceland, Liechtenstein and Norway. “Dr William Sly’s science for this treatment has been around for over 25 years and we are honored to be able to develop and finally make this medicine available to MPS VII patients and families in Europe, people who did not know whether a therapy would ever be available to them,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RARE earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 Ultragenyx Pharmaceutical Inc Earnings Call
Markit•2 months agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Markit•2 months agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- Zacks•2 months ago
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.
- Zacks•2 months ago
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.95% and 180.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Ultragenyx: 2Q Earnings Snapshot
The Novato, California-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring gains, were $1.87 per share. The results topped Wall Street expectations. The average estimate ...
- GlobeNewswire•2 months ago
Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif, Aug. 02, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
